Kornimate/medical-research-clean huggingface dataset:
ccrc: effects of partially hydrolyzed whey peptides (phwp) on weight loss in individuals with the metabolic syndrome (mets)

Conditions: Metabolic Syndrome; Overweight

Summary: the aim of this study is to compare the effects of two different protein supplements (partially hydrolyzed whey protein, phwp vs. partially hydrolyzed gelatin, phg) on weight loss in obse individuals with metabolic syndrome (mets). these two supplements will contain equal amounts of protein but differ considerably in their amino acid contents. whey protein is rich in essential amino acids whereas gelatin is rich in proline. in obese individuals with mets, the hypotheses are: * phwp will augment fat-mass loss and increase lean-mass to fat-mass ration more than phg. * phwp will improve insulin action more than phg. * phwp will decrease cardiovascular disease risk more than phg.

the metabolic syndrome (mets) is a clinical disorder characterized by the following problems: obesity, especially located in the waist area, elevated blood fats (lipids), high blood pressure and insulin resistance. the mets affects one third of the adult population in the usa and increases the risks for both diabetes and hardening of the arteries, leading to heart attacks and strokes. the best treatment for improving the symptoms of mets is weight loss. in previous studies, it has been demonstrated that whey protein (wp) supplementation increased weight loss and especially fat-mass loss in obese, insulin resistant women when compared to carbohydrates. we now propose to compare wp to another protein source in patients with the mets during weight loss. in addition, we will use a special preparation called partially hydrolyzed whey protein, which may have specific properties that increase fat mass loss.

Eligibility criteria:
inclusion criteria: * clinical diagnoses of metabolic syndrome (at least 3/5 of the following) * waist circumference: men: \>40 in women: \>35 in * blood pressure: \>135/\>85 mm hg * triglycerides: \>150 mg/dl * hdl-cholesterol: men: \<40 mg/dl women: \<50 mg/dl * fasting glucose: \>100 mg/dl * ages 18 to 65 years * bmi range of 27 to 42 kg/m\^2 * body weight \<300 lbs * weight stable for 3 months exclusion criteria: * subjects who habitually consume protein supplements or have eating disorders * recent delivery (within 12 months), lactation, pregnancy or intention to become pregnant * type 2 diabetes, kidney disease, liver disease, anemia, gout, cancer, untreated thyroid disease, gastrointestinal disease, other metabolic diseases or malabsorption syndromes * triglyceride \>500 mg/dl, cholesterol \>260 mg/dl * use of insulin sensitizers, lipid lowering medication or ace inhibitors * use of anti-obesity medications or supplements for at lease 6 months prior to start of study * known allergy or adverse reaction to protein and dairy products (including lactose)

Keywords: metabolic syndrome mets obesity partially hydrolyzed whey protein partially hydrolyzed gelatin phwp phg weight loss
ppi vs h2ra in patients with helicobacter pylori-negative idiopathic bleeding ulcers

Conditions: Peptic Ulcer

Summary: the aim of this study is to compare the efficacy of a proton pump inhibitor (lansoprazole) and a histamine-2 receptor antagonist (famotidine) in preventing recurrent ulcer bleeding in patients with a history of h. pylori-negative idiopathic peptic ulcers.

peptic ulcer disease used to be caused by a bacterial infection (helicobacter pylori) in the stomach or the use of certain painkillers (nonsteroidal anti-inflammatory drugs or nsaids). however, there has been an increasing trend of peptic ulcer disease with unknown cause (idiopathic ulcer) worldwide since the last decade. studies in north america found that idiopathic ulcers accounted for 11% and 44% of all peptic ulcers. a meta-analysis of 7 us trials found that 20% of patients with h. pylori-associated ulcers had recurrent ulcers within 6 months, despite successful cure of h. pylori infection and no reported use of nsaids. in a pooled analysis of 6 clinical trials with a total of 2900 patients, 27% of duodenal ulcers were not associated with nsaid use or h. pylori infection. the emerging problem of h. pylori-negative idiopathic peptic ulcers is not only limited to western countries. previously, h. pylori-negative idiopathic peptic ulcers accounted for less than 5% of peptic ulcers in asia. a recent korean study reported that the proportion of peptic ulcers not associated with h. pylori infection or nsaid use was over 20%.

Eligibility criteria:
inclusion criteria: 1. a history of h. pylori-negative idiopathic peptic ulcers, defined as 1. no exposure to aspirin, nsaids or drugs of unknown nature including traditional chinese medicine within the 4 weeks before hospitalization; 2. biopsies taken during endoscopy must be negative for both the urease test and histology for h. pylori in the absence of acid suppressive therapy; and 3. no other causes of ulceration identified. 2. endoscopically confirmed ulcer healing 3. age \>18 years old 4. informed consent exclusion criteria: 1. concomitant steroid or anticoagulant 2. concomitant use of nsaids, aspirin or cox2 inhibitors 3. previous gastric surgery 4. requirement of maintenance ppi (e.g. reflux oesophagitis) 5. advanced comorbidity (defined as asa 4 or above) or active malignancy 6. subjects who are pregnant or lactating, or is intending to become pregnant before, during, or within 1 month after participating in this study 7. subjects who have known hypersensitivity or allergies to any component of lansoprazole or famotidine. 8. subject who has current or historical evidence of zollinger-ellison syndrome or other hypersecretory condition

Keywords: h. pylori-negative idiopathic peptic ulcers recurrent ulcer bleeding
boncure study: a study of monthly bonviva (ibandronate) in women with post-menopausal osteoporosis on bisphosphonate therapy.

Conditions: Post-Menopausal Osteoporosis

Summary: this single arm study will assess participant preference for monthly bonviva, versus daily or weekly alendronate or risedronate, in the treatment of postmenopausal osteoporosis. participants currently on a daily or weekly regimen of bisphosphonate therapy (alendronate or risedronate) will answer a questionnaire to identify participants who may benefit from a monthly bonviva regimen. eligible participants will then discontinue their present bisphosphonate treatment, and switch to monthly bonviva 150mg per oral (po). at the beginning and end of bonviva treatment, all participants will complete an osteoporosis patient satisfaction questionnaire. the anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.


Eligibility criteria:
inclusion criteria: * post-menopausal women; * \>=3 months daily or weekly alendronate or risedronate for treatment or prevention of post-menopausal osteoporosis. exclusion criteria: * inability to stand or sit in an upright position for at least 60 minutes; * hypersensitivity to bisphosphonates; * treatment with other drugs affecting bone metabolism; * abnormalities of the oesophagus, which delay oesophageal emptying.
the pilot study of medical device-neuclare for patients with idiopathic normal pressure hydrocephalus (inph)

Conditions: Idiopathic Normal Pressure Hydrocephalus (iNPH)

Summary: this clinical trial aims to explore the effectiveness and safety of gait improvemen of neuclare, a science medical device, for patients with idiopathic normal pressure hydrocephalus (inph) through methods such as timed up \& go test (tug), 10m gait , inph grading scale), etc, gait improvement before and after using neuclare will be evaluated.


Eligibility criteria:
inclusion criteria: * adults aged 60 to 90, regardless of gender * individuals exhibiting gait disturbances along with at least one of the following symptoms: cognitive impairment or urinary incontinence * evans' index \> 0.3) * when the symptoms in 2) and 3) cannot be fully explained by other neurological or non-neurological diseases * diagnosis of inph based on the investigator's clinical judgement based on criteria as described in the inph guidelines exclusion criteria: * patient with pathological lesions in the brain identified by mri * a person who is confirmed to have organic brain lesions (e.g., cerebral edema, cerebral hemorrhage, cerebral infarction, cerebrovascular malformation, brain tumor, etc.) on a brain mri. * patients with metabolic disorders such as thyroid dysfunction, hyperglycemia, hypoglycemia, liver or kidney dysfunction, and long-term use of drugs that will cause cognitive decline (e.g., anticholinergic drugs) * history of psychiatric disorder other than the inclusion criteria. * a person with a severe history of cancer/tuberculosis * a person who has contact dermatitis or sensitive skin abnormalities * patients with a high fever of 40 degrees celsius or higher based on eardrum body temperature * a person whose bleeding is identified due to a common procedure or surgery that may affect vital signs * a person who is unable to perform mri tests * a person with an allergic reaction to mri contrast agents such as definity or gadovist. * other cases where the investigator judged that it is difficult to participate in the study * patient with behavioral and psychological symptoms of dementia (bpsd) that make cooperation in the clinical trial difficult * patients with severe cognitive impairment, defined as an mmse score of 17 or below * patients who have undergone shunt surgery in the past year * patients with a history of uncontrolled thyroid, liver, or kidney dysfunction * patients taking medications that affect gait, cognition, or urinary tract function and who have had a change in medication regimen within the past 3 months. * patients who have undergone a cerebrospinal fluid drainage test within the past 1 month.
xrp6258 plus prednisone compared to mitoxantrone plus prednisone in hormone refractory metastatic prostate cancer

Conditions: Neoplasms; Prostatic Neoplasms

Summary: this is a randomized, open-label, multi-center study comparing the safety and efficacy of xrp6258 plus prednisone to mitoxantrone plus prednisone in the treatment of hormone refractory metastatic prostate cancer previously treated with a taxotere®-containing regimen. the primary objective is overall survival. secondary objectives include progression free survival, overall response rate, prostate-specific antigen (psa) response/progression, pain response/progression, overall safety, and pharmacokinetics. patients will be treated until disease progression, death, unacceptable toxicity, or for a maximum of 10 cycles. patients will have long-term follow-up for a maximum of up to 2 years.


Eligibility criteria:
inclusion criteria 1. histologically or cytologically confirmed adenocarcinoma of the prostate that is refractory to hormone therapy and previously treated with a taxotere®-containing regimen. 2. documented progression of disease (demonstrating at least one visceral or soft tissue metastatic lesion, including a new lesion). patients with non-measurable disease must have documented rising prostate-specific antigen (psa) levels or appearance of new lesion. 3. surgical or hormone-induced castration 4. life expectancy \> 2 months 5. eastern cooperative oncology group (ecog) performance status 0 - 2 exclusion criteria 1. previous treatment with mitoxantrone 2. previous treatment with \<225 mg/m\^2 cumulative dose of taxotere (or docetaxel) 3. prior radiotherapy to ≥ 40% of bone marrow 4. surgery, radiation, chemotherapy, or other anti-cancer therapy within 4 weeks prior to enrollment in the study 5. other prior malignancy, except for adequately treated superficial basal cell skin cancer, or any other cancer from which the patient has been disease-free for less than 5 years 6. known brain or leptomeningeal involvement 7. other concurrent serious illness or medical conditions 8. inadequate organ function evidenced by unacceptable laboratory results the investigator will evaluate whether there are other reasons why a patient may not participate.

Keywords: cancer prostate
periodontal osseous wall piezosplitting and edta root surface etching

Conditions: Periodontitis

Summary: this study was designed to investigate the use of minimally invasive piezo knife to harvest vascularized interceptal bone pedicle in treating intrabony defects.

sixteen non-smoking patients with severe chronic periodontitis participated in this prospective, randomized clinical study. patients were randomly assigned into one of a 2 groups (8 patients each): bone substitute grafting of the intrabony defect, control group (gr1), intrabony defect osseous wall swaging (ows) combined xenograft (gr2). in both groups root surfaces where treated with a neutral 24% edta gel and saline irrigation. clinical and radiographic measurements were reassessed at 6 months after surgery.

Eligibility criteria:
inclusion criteria: 1. good compliance with plaque control instructions following initial therapy 2. teeth involved were all vital with no mobility ; 3. each subject contributed a single predominately 2 or 3-wall intrabony interproximal defect around premolar or molar teeth without furcation involvement; exclusion criteria: 1. no systemic diseases which could influence the outcome of therapy; 2. absence of periodontal treatment during the previous year.
hospice volunteer community，dying patient prepare spirtal care

Conditions: Hospital Acquired Condition

Summary: due to the aging population, the cases of elderly disability and death caused by chronic diseases and cancer are also increasing; thus increasing the demand and trend of community palliative care. anning volunteers are members of the anning team and play an integral role in the care of the "whole community". partners who can provide psychosocial support in fear, grief, informal care, and "individualized care" can focus on patient and family needs and give their time and presence. and make up for the shortage of medical manpower. assist nurses to take care of patients together, which is an important support for nursing care. in the community, an ning volunteers are an important help to closely care for patients and support family members to take care of them at home and fulfill their wish of dying at home. in view of the community's peaceful home care, the trend and importance of hospice at home, it is necessary to cooperate with the "volunteers" of the tranquility team. inquiry only a few papers mentioned anning volunteers' service history and research on the meaning of life, but there was a lack of in-depth and systematic discussions on anning volunteers, including their motivation, training, process, care effectiveness, impact on training volunteer organization management, and volunteer retention. therefore, the motivation of the research was aroused, and it was hoped to use grounded theory to explore the motivation and process of becoming an anning volunteer, and to identify related concepts, and finally establish a theoretical framework to describe the relevant decision-making mentality. also serves as a reference for volunteer organization management training and retention of palliative care volunteers.

the purpose of this study is to use grounded theory to explore the motivation and process of becoming a tranquility volunteer, identify relevant concepts, and finally establish a theoretical framework to describe the relevant decision-making process. this study adopts semi-structured in-depth interviews and semi-structured one-on-one interviews to collect data. during the interview process, according to the actual situation, the interview questions will be flexibly fine-tuned according to the data analysis results. the data coding of grounded theory is divided into three levels: open decoding, axial decoding and selective decoding; through these three levels of coding, the data are decomposed, compared, conceptualized and integrated, and finally a theory is formed.

Eligibility criteria:
inclusion criteria: 1. adults aged 18 or above (2) community hospice volunteers, who have served for more than one year (including one year), are currently serving volunteers or have stopped serving volunteers (3) can speak mandarin or taiwanese communicate. exclusion criteria: * those who could not understand or conduct the interview due to any physical or psychological or cognitive factors were excluded. * no dmentia stroke

Keywords: hospice volunteer
virus as treatment of c. difficile infection (vision)

Conditions: Clostridium Difficile Infections

Summary: fecal virome transplantation (fvt) has in small studies shown benefit in the treatment of recurrent c. difficile infection. in the vision study we will treat patients with recurrent c. difficile infection with fvt capsules and compare the treatment with fecal microbiota transplantation (fmt) capsules. both will be following af standard treatment of antibiotics (vancomycin)

in the vision study we will treat patients with recurrent c. difficile infection (cdi) with fvt capsules and compare the treatment with fecal microbiota transplantation (fmt) capsules. patients will be randomised to receive either fmt or ftv capsules. patients will be followed for one year to investigate the risk of a new recurrence of cdi. patients and researchers involved in the treatment of the patients will be blinded to the treatment

Eligibility criteria:
inclusion criteria: * recurrent c. difficile infection (first or second recurrence) * understand danish exclusion criteria: * serious food allergy (anaphylaxis) * other pathogenic bacteria/virus in stool sample prior to inclusion * inability to ingest capsules * gastrointestinal perforation in the 180 days prior to inclusion * previous treatment with fmt og rectal bacteriotherapy in the 180 days prior to inclusion * short bowel syndrome * pregnancy or planning of pregnancy * participation in other clinical trial in the 30 days prior to inclusion * stoma * other condition where fmt is considered contraindicated

Keywords: fecal virome transplantation fecal microbiota transplantation
social incentives to increase mobility

Conditions: Pneumonia; Diabetes; Congestive Heart Failure; Chronic Obstructive Pulmonary Disease

Summary: this study aims to assess the effectiveness of a social incentive-based gamification intervention to increase physical activity in the 3 months after hospital discharge.

this study aims to assess the effectiveness of a social incentive-based gamification intervention to increase physical activity in the 3 months after hospital discharge. to do this, the investigators will conduct a two-arm randomized, controlled trial during the 3-months after hospital discharge comparing a control group that uses a wearable device to track physical activity to an intervention group that uses the same wearable devices and receives a supportive social incentive-based gamification intervention to adhere to a step goal program. patients will be enrolled during hospitalization from medicine and oncology floors into three phases. in phase 1 (hospitalization), patients inpatient step counts will be monitored. in phase 2 (week 1 post-discharge), patients will have a baseline step count estimated. in phase 3 (weeks 2-13 post-discharge), patients will be randomly assigned to the control or intervention group. patients will be considered enrolled in the trial if they complete the run-in periods (phases 1 and 2) and then are randomized into phase 3. the enrollment phase will be part of another randomized trial which evaluates the impact of three recruitment strategies on patient enrollment. this trial will be completed and unmasked to patients before they begin the phase 1 of our study. the investigators will also explore patients' physical activity while in the hospital and if that differs across floors that have or have not deployed a nursing mobility protocol. changes in patient functional decline and 30-day hospital readmission will also be explored.

Eligibility criteria:
inclusion criteria: * age 18 or older * admitted to medicine or oncology floor in the hospital exclusion criteria: * inability to provide informed consent * does not have daily access to a smartphone compatible with the wearable device * already enrolled in another physical activity program * inpatient mobility score of 0 or 1 indicating that physical activity is not appropriate for the patient * any other medical conditions that would prohibit participation in a 3-month physical activity program * unable to complete the run-in phases (e.g. not discharged from the hospital within 60 days of enrolling; not willing to use the wearable device for the 3-month post-discharge intervention).
effect of flozin (dapagliflozin) administration on myocardial and peripheral vascular remodeling

Conditions: Heart Failure

Summary: the aim of this study is to assess the effect of treatment with flozin (dapagliflozin 10mg once a day) on haemodynamic parameters and myocardial and peripheral vascular remodeling in patients with nyha class ii-iii heart failure.

in the available literature, there are reports of beneficial effects of flozins on improving myocardial systolic and diastolic function and isolated reports of effects on regression of organ damage (heart, vessels). these drugs significantly improve the prognosis of patients with heart failure, reduce total and cardiovascular mortality, reduce the number of exacerbations and the need for hospitalization, and have a beneficial effect on improving quality of life regardless of coexisting diabetes. new properties demonstrating the pleiotropic effect of the flozins are constantly being discovered. drugs in this group are highly potent, selective and reversible inhibitors of the sodium ion-dependent glucose cotransporter 2 (sglt2). the flozins have a low risk of side effects.

Eligibility criteria:
inclusion criteria: * diagnosed heart failure nyha class ii and iii * consent to participate in the study * patients should already be receiving treatment with an ace inhibitor or sacubitril/valsartan or sartans, a beta-blocker, and an mra, and should start on sglt2i as part of therapy enhancement exclusion criteria: -